Press Release: Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
Press Release: Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
Press Release: Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
新聞稿：Enzo Biochem報告2021財年第二季度業績；公司提供領導力和公司最新情況
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
恩佐生物化工公司報告2021財年第二季度業績；公司提供領導力和公司最新情況
-- Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemic -- Second quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix -- Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-year -- Achieved adjusted EBITDA at $4.3 million for the quarter with increases in sequential and YOY profitability -- EPS of $0.05 for the quarter vs. EPS loss of ($0.16) in Q2 2020 -- Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board -- Executive search firm Korn Ferry engaged to identify CEO candidates -- Gary M. Huff, former LabCorp Diagnostics CEO, named Strategic Consultant to Board -- Enzo retains Cain Brothers to help identify, evaluate, and execute strategic initiatives
第二季度臨牀實驗室收入為2,400萬美元，由於產品組合的改善，產量和價格大幅增長，因此增長了92%。合併季度毛利率為50%，比去年同期提高了2000個基點。本季度調整後的扣除利息、折舊及攤銷前利潤為430萬美元，環比和同比盈利能力都有所提高。--本季度每股收益為0.05美元，而每股收益虧損為0.16美元。--第二季度的每股收益為0.05美元，而每股收益虧損為0.16美元。--第二季度的總收入為3,150萬美元，同比增長62%。第二季度臨牀實驗室的收入為2,400萬美元，而由於產品結構的改善，產量和價格均大幅增長。--合併季度毛利率為50%，比去年同期提高了2,000個基點。一旦董事會確定並聘請了一位合格的繼任者，恩佐將辭去首席執行官一職，過渡到公司的科學職位--聘請高管獵頭公司光輝國際(Korn Ferry)確定首席執行官候選人--LabCorp Diagnostics前首席執行官、被任命為董事會戰略顧問的加里·M·赫夫(Gary M.Huff)--恩佐保留凱恩兄弟公司(Cain Brothers)，幫助確定、評估和執行戰略舉措
Conference call and live webcast scheduled for today,
今天安排了電話會議和網絡直播，
Monday, March 15, 2021 at 4:30 pm (ET)
2021年3月15日(星期一)下午4：30(美國東部時間)
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2021 and provided a business update on recent corporate and operational developments.
紐約，2021年3月15日(環球通訊社)-領先的生物科學和診斷公司Enzo Biochem，Inc.(紐約證券交易所代碼：ENZ)今天公佈了截至2021年1月31日的第二季度財務業績，並提供了最近公司和運營發展的最新業務情況。
"The Company's strong financial performance in the second quarter is another reflection of the strength of our new business model for integrated diagnostic product and services. The high gross margins achieved this quarter further validate the strength of Enzo's strategy," said Elazar Rabbani, Ph.D., Enzo's Chairman and CEO. "These results are especially indicative of the advancements we have made in development of proprietary products, notably our versatile GENFLEX(TM) molecular diagnostic platform, as well as our integrated end-to-end business strategy that ranges from research through final diagnostic products and services."
恩佐公司董事長兼首席執行官埃拉扎爾·拉巴尼博士説：“公司第二季度的強勁財務表現再次反映了我們在集成診斷產品和服務方面的新業務模式的實力。本季度實現的高毛利率進一步證實了恩佐公司戰略的實力。”這些結果特別表明我們在專利產品開發方面取得的進步，特別是我們多功能的GENFLEX(商標)分子診斷平臺，以及我們從研究到最終診斷產品和服務的綜合端對端業務戰略。“
Enzo's financial improvement from an operating loss of $16.2 million in 1H 2020 to an operating profit of $2.2 million in 1H 2021, an $18.4 million improvement, supported by management's strategic shift to addressing the COVID-19 pandemic on its proprietary GENFLEX(TM) platform as well as cost efficiencies identified and executed by the Company. These operational measures were achieved despite staff limitations, supply chain interruptions, and other unprecedented circumstances caused by the pandemic.
恩佐的財務改善，從2020年上半年1,620萬美元的營業虧損到2021年上半年220萬美元的營業利潤，這是1,840萬美元的改善，這得益於管理層在其專有的GENFLEX(TM)平臺上應對新冠肺炎大流行的戰略轉變，以及公司確定和執行的成本效益。儘管人員有限，供應鏈中斷，以及大流行造成的其他前所未有的情況，這些業務措施仍得以實現。
"Our open system approach allows for the highest levels of flexibility and adaptability in the post COVID-19 environment," said Barry Weiner, Enzo's President. "Our GENFLEX(TM) platform enables laboratories to use third-party or their own reagents on this open platform with ease and flexibility. Through this platform, we can provide substantially lower costs for molecular testing and address reimbursement pressure in one of the fastest growing segments of the clinical testing market."
恩佐總裁巴里·韋納説：“我們的開放系統方法允許在後新冠肺炎環境中實現最高水平的靈活性和適應性。我們的GENFLEX(TM)平臺使實驗室能夠輕鬆、靈活地在這個開放平臺上使用第三方或他們自己的試劑。通過這個平臺，我們可以大大降低分子測試的成本，並解決臨牀測試市場增長最快的領域之一的報銷壓力。“
"We remain committed to our growth strategy and expect that the higher margins achieved by the vertically integrated model of COVID-19 testing can be extended to a range of other molecular tests as well as key platforms such as immunohistochemistry (IHC) and cytology, both of which can face challenges as a result of widespread use of closed system platforms," continued Mr. Weiner. "We are currently validating test menus and panel extensions to drive utility in the high-volume molecular testing space through deployment of Enzo's internal sales and marketing operations as well as with industry partners."
韋納先生繼續説：“我們將繼續致力於我們的增長戰略，並預計新冠肺炎測試垂直整合模式實現的更高利潤率可以擴展到一系列其他分子測試以及免疫組織化學和細胞學等關鍵平臺，由於封閉系統平臺的廣泛使用，這兩個平臺都可能面臨挑戰。”我們目前正在驗證測試菜單和麪板擴展，以通過部署Enzo的內部銷售和營銷業務以及與行業合作伙伴來推動大容量分子測試領域的實用性。“
After years of dedicated service, Dr. Elazar Rabbani, Founder and CEO, will remain a Director of the Company and will step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board. To fully capitalize on the potential of Enzo's business model, the Company and the Board of Directors have retained the global search firm Korn Ferry to conduct the CEO search.
經過多年的敬業服務，公司創始人兼首席執行官埃拉扎爾·拉巴尼博士將繼續擔任公司董事，一旦董事會確定並聘用合格的繼任者，他將辭去首席執行官一職，過渡到公司的科學職位。為了充分利用恩佐商業模式的潛力，公司和董事會聘請了全球獵頭公司光輝國際(Korn Ferry)進行CEO招聘。
In addition, the Company also announced that Gary Huff, the former CEO of LabCorp Diagnostics, will serve as a strategic consultant to the Board. Mr. Huff is an industry veteran who held multiple positions of increasing responsibility at LabCorp and demonstrated a strong history of leadership and business acumen. He was formerly CEO of Baylor Genetics Laboratories where he provided leadership and guidance on the continuous development of their product pipeline.
此外，該公司還宣佈，LabCorp Diagnostics前首席執行官加里·赫夫(Gary Huff)將擔任董事會的戰略顧問。赫夫是一位業內資深人士，曾在LabCorp擔任過多個職位，承擔着越來越多的責任，並表現出強大的領導力和商業敏鋭性。他曾是貝勒遺傳實驗室的首席執行官，在那裏他為他們的產品線的持續發展提供領導和指導。
To assist with strategic initiatives, the Company has also retained Cain Brothers, a healthcare investment banking firm, to help identify, evaluate and execute strategic and commercial opportunities.
為了協助戰略計劃，該公司還聘請了醫療保健投資銀行公司凱恩兄弟(Cain Brothers)來幫助識別、評估和執行戰略和商業機會。
Second Quarter 2021 and Recent Business Highlights
2021年第二季度和最近的業務亮點
-- Announced results of an analysis showing that tests processed on the Company's proprietary GENFLEX(TM) molecular diagnostic platform are successfully able to detect the presence of currently known variants of COVID-19. While the Company's PCR testing does not distinguish between different variants, positive samples can be further analyzed for variant identification. Rapid antigen tests currently available in the marketplace do not have this capability. -- Received an expansion of its Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) authorizing the use of pooled samples containing up to five individual swab specimens with the Company's AMPIPROBE(R) SARS-Cov-2 Test System utilizing tests on three different platforms including Enzo's proprietary GENFLEX(TM) automated high-throughput platform. -- Received a U.S. Patent for polyclonal antibodies against osteoporosis drug target sclerostin. This patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis.
--公佈的一項分析結果顯示，在該公司專有的GENFLEX(TM)分子診斷平臺上進行的測試能夠成功地檢測到目前已知的新冠肺炎變種的存在。雖然該公司的PCR檢測沒有區分不同的變種，但陽性樣本可以進一步分析以識別變種。目前市場上可用的快速抗原檢測沒有這種能力。--從美國食品和藥物管理局(FDA)獲得了緊急使用授權(EUA)的擴展，授權在該公司的AMPIPROBE(註冊商標)SARS-CoV-2測試系統中使用包含最多5個單獨拭子樣本的混合樣本，利用三個不同平臺上的測試，包括恩佐公司專有的GENFLEX(TM)自動化高通量平臺。--獲得了針對骨質疏鬆症藥物靶標硬化劑的多克隆抗體的美國專利。這項專利是更廣泛的美國和國際專利家族中的一員，該家族還包括用於治療骨質疏鬆症等骨骼疾病的已頒發專利和正在申請的專利，其中包括單克隆抗體和用於抑制硬化素的小合成肽。
Second Quarter 2021 Financial Results
2021年第二季度財務業績
-- Total second quarter revenue was $31.5 million, an increase of 62% from $19.4 million in the second quarter last year. The gains reflected continued increased activity, particularly related to COVID-19. Consolidated gross margin was 50.3%, a 2,030 basis points improvement, vs 30.0% in the year ago period. -- Enzo Clinical Lab revenues totaled $24.0 million, an increase of 92% from $12.5 million in the second quarter last year. This performance was primarily driven by services accession count exceeding 330,000 in the quarter compared to approximately 200,000 a year ago, an increase of nearly 65% year-over-year. Clinical services margin advanced to 51.2%, from 18.1% in the year-ago comparable period and 38.8% in the preceding quarter, largely due to testing mix and ongoing cost-saving initiatives. -- Enzo Life Sciences revenue was $7.5 million, an increase of 9% compared with $6.9 million in the year ago period. The average product order value increased 18% during the period, due mainly to servicing higher value markets. Gross margin was 47.4%, lower than the 51.5% gross margin in the year ago period, but was flat when accounting for intercompany sales. -- Research and development expenses declined 24% to $0.8 million, or 2.6% of total revenues, from $1.1 million, or 5.5% of total revenues, in the year ago period. Selling, general and administrative expenses of $11.0 million rose slightly from $10.7 million in year ago period, although SG&A margin declined by more than 2000 basis points due to better fixed cost leverage as a result of vertical integration and cost efficiency measures. -- GAAP net income totaled $2.3 million, or $0.05 per share, compared with a loss of ($7.7) million, or ($0.16), in the year-ago quarter, an improvement of almost $10 million. Adjusted EBITDA in the quarter totaled $4.3 million, versus an adjusted EBITDA loss of $5.4 million in the second quarter of 2020. The year-over-year increase was driven mainly by improvement in gross margin (from COVID-19 testing and lower reagent and reference lab costs) and lower SG&A expenses from headcount efficiencies, lower intangibles amortization, and reduced travel. -- Cash and cash equivalents totaled $44.5 million as of January 31, 2021, slightly lower than the $47.9 million at the end of fiscal year 2020, due to investments in inventory, higher accounts receivable and capital expenditures, and lower accounts payable. Working capital amounted to $40.0 million, compared to $36.0 million as of July 31, 2020. As of January 31, 2021, the Company had 48.2 million shares outstanding.
--第二季度總收入為3150萬美元，比去年第二季度的1940萬美元增長了62%。這一增長反映出活動繼續增加，特別是與新冠肺炎相關的活動。合併毛利率為50.3%，比去年同期的30.0%提高了2030個基點。--恩佐臨牀實驗室的總收入為2400萬美元，比去年第二季度的1250萬美元增長了92%。這一業績的主要推動因素是本季度服務註冊數量超過33萬，而一年前約為20萬，同比增長近65%。臨牀服務利潤率從去年同期的18.1%和上一季度的38.8%上升到51.2%，這主要是由於測試組合和持續的成本節約計劃。--恩佐生命科學公司的收入為750萬美元，比去年同期的690萬美元增長了9%。在此期間，平均產品訂單價值增長了18%，這主要是由於服務於更高價值的市場。毛利率為47.4%，低於去年同期的51.5%，但計入公司間銷售額後持平。-研究和開發費用下降了24%，從去年同期的110萬美元降至80萬美元，佔總收入的2.6%，佔總收入的5.5%。銷售、一般和行政費用為1100萬美元，略高於去年同期的1070萬美元，儘管由於垂直整合和成本效率措施改善了固定成本槓桿，SG&A利潤率下降了2000多個基點。--GAAP淨收入總計230萬美元，或每股0.05美元，而去年同期虧損(770萬美元)，或每股虧損(0.16美元)，改善近1000萬美元。本季度調整後的EBITDA總額為430萬美元, 相比之下，2020年第二季度調整後的EBITDA虧損為540萬美元。同比增長的主要原因是毛利率的提高(來自新冠肺炎測試和較低的試劑和參考實驗室成本)，以及員工效率、無形資產攤銷減少和差旅減少帶來的SG&A費用減少。-截至2021年1月31日，現金和現金等價物總計4450萬美元，略低於2020財年末的4790萬美元，原因是庫存投資、應收賬款和資本支出增加以及應付賬款減少。營運資本為4000萬美元，而截至2020年7月31日為3600萬美元。截至2021年1月31日，該公司有4820萬股流通股。
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 15, 2021 16:05 ET (20:05 GMT)
2021年3月15日東部時間16：05(格林尼治標準時間20：05)
譯文內容由第三人軟體翻譯。